SC Filed 2020-12-17 Event — SEC 0001178913-20-003385 →

Arkin Moshe → Keros Therapeutics, Inc. KROS

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 20/100

Passive Schedule 13G filer baseline
Held by 1 tracked 13F institutional manager
Elevated short days-to-cover (6.5 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

5 13D/G filings on this issuer

4 other filings besides this one

Filer Track Record

10 filings by this filer

9 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 6.51

1,136,901 shares short · -1.1% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $791K

Point72 Asset Mgmt

Other 13D/G Filings on Keros Therapeutics, Inc.

Filed	Form	Filer	Stake	Shares
2026-07-17	SCHEDULE 13G	BlackRock Portfolio Management LLC	—	—	view →
2025-04-28	SCHEDULE	ADAR1 Capital Management, LLC	13.29%	5,390,964	view →
2020-11-25	SC	Arkin Moshe	—	—	view →
2020-11-20	SC	ORBIMED ADVISORS LLC	—	—	view →

Other Filings by Arkin Moshe

Filed	Form	Issuer	Stake	Shares
2026-09-09	SCHEDULE 13D	Odysight.ai Inc.	33.34%	4,135,724	view →
2024-07-01	SC	Eiger BioPharmaceuticals, Inc.	—	—	view →
2024-04-08	SC	Sol-Gel Technologies Ltd. SLGL	—	—	view →
2023-03-20	SC	Sol-Gel Technologies Ltd. SLGL	—	—	view →
2020-11-25	SC	Keros Therapeutics, Inc. KROS	—	—	view →
2020-04-20	SC	Sol-Gel Technologies Ltd. SLGL	—	—	view →
2019-12-19	SC	Aclaris Therapeutics, Inc. ACRS	—	—	view →
2019-11-21	SC	Aclaris Therapeutics, Inc. ACRS	—	—	view →
2019-06-03	SC	UroGen Pharma Ltd. URGN	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →